Evidence map›Paper›PMID 41216499›Full record

ArticleGenes & diseases2026

Synergistic anti-tumor activity of ciclopirox olamine and metformin in triple-negative breast cancer.

Yakun Wu, Hui Lyu, Congcong Tan, Margaret E Larsen, Shou-Ching Tang, Shile Huang, Bolin Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yakun WuDepartments of Interdisciplinary Oncology and Genetics, LSU LCMC Health Cancer Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA.
Hui LyuDepartments of Interdisciplinary Oncology and Genetics, LSU LCMC Health Cancer Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA.
Congcong TanDepartments of Interdisciplinary Oncology and Genetics, LSU LCMC Health Cancer Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA.
Margaret E LarsenDepartments of Interdisciplinary Oncology and Genetics, LSU LCMC Health Cancer Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA.
Shou-Ching TangDepartment of Medicine, LSU LCMC Health Cancer Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA.
Shile HuangDepartment of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, Shreveport, Louisiana 71103, USA.
Bolin LiuDepartments of Interdisciplinary Oncology and Genetics, LSU LCMC Health Cancer Center, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA.

Funding

HER3-PHF8 signaling axis in triple-negative breast cancer progressionR01CA266269 · NCI · LSU HEALTH SCIENCES CENTER · PI Bolin Liu · 2023 to 2026
$1.6M
NCI NIH HHS R01 CA266269
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41216499
PMCPMC12596565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.